T2DM and CKD patients with albuminuria T2DM and CKD patients with albuminuria
Conditions
Interventions
empagliflozin 10 mg/day plus linagliptin 5 mg/day,standard of care treatment
Experimental Drug,No Intervention No treatment
empagliflozin/linagliptin,standard treatment
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Age more than 18 years T2DM eGFR 30-59 ml/min/1.73m2 Stable glycemic treatment 3 months No treatment adjusted with anti-HT within 1 month
Exclusion criteria
Exclusion criteria: Sepsis/ any organ infection Current history of urinary and genital tract infection History of diabetic ketoacidosis Pregnancy Pancreatic and active liver disease Polycystic kidney disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in urine L-FABP urinary L-FABP level at baseline, and at 12 weeks after treatment urinary L-FABP level by ELISA method | — |
Secondary
| Measure | Time frame |
|---|---|
| urine albumin creatinine ratio at baseline before and at 12 weeks after treatment urine albumin creatinine ratio by standard laboratory of center | — |
Countries
Thailand
Contacts
Public ContactSaranyapong Runprapan
Department of Internal Medicine, Phramongkutklao Hospital
Outcome results
None listed